TOP > 外国特許検索 > NUCLEIC ACID APTAMER

NUCLEIC ACID APTAMER NEW

外国特許コード F210010294
整理番号 (S2019-0245-N0)
掲載日 2021年1月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2020JP020119
国際公開番号 WO 2020235635
国際出願日 令和2年5月21日(2020.5.21)
国際公開日 令和2年11月26日(2020.11.26)
優先権データ
  • 特願2019-096035 (2019.5.22) JP
発明の名称 (英語) NUCLEIC ACID APTAMER NEW
発明の概要(英語) A nucleic acid aptamer that is capable of forming a guanine quadruplex structure in the presence of a cation and has a cell membrane permeability, wherein the nucleic acid aptamer comprises first, second, third and fourth regions forming the guanine quadruplex structure and connection regions A, B and C positioned respectively between the first and second regions, between the second and third regions and between the third and fourth regions; the first region has the base sequence represented by SEQ ID NO: 1; the second, third and fourth regions each have the base sequence represented by SEQ ID NO: 2; and at least one region selected from the group consisting of the connection regions A, B and C is capable of specifically binding to a target molecule in the presence of a cation.
従来技術、競合技術の概要(英語) BACKGROUND ART
In recent years, antibody pharmaceuticals have become highly aggressive as therapeutic agents for cancer, but in addition to the high drug value, the type of disease-associated protein that can be handled is a plateau, and the limitation of antibody pharmaceuticals has also been seen. Therefore, development of post-antibody pharmaceuticals having a maternal structure different from that of antibodies is strongly desired. DNA / RNA aptamers formed from single-stranded DNA or RNA and having high binding capacity and selectivity with respect to biomolecules containing proteins are inexpensive to synthesize and have low antigenicity. therefore, attention is focused on as target recognition molecules instead of antibodies. Previously approved aptamer drugs include pegaptanib (trade name "Macugen", U.S. approved 2004, and Japanese approved 2008), which are drugs for treating age-related macular degeneration (, for example, see Patent Document 1.
However, antibody pharmaceuticals and nucleic acid aptamer pharmaceuticals approved thus far cannot permeate through the cell membrane, and thus the target is limited to extracellular. Therefore, it is desirable to develop a molecular targeting drug that can permeate through the cell membrane while maintaining the high molecular recognition ability and binding ability of antibodies and nucleic acid aptamers.
Furthermore, as a method for introducing a protein such as an antibody into a cell, a method using uptake into a cell by fusion or mixing with a transmembrane peptide and a method for introducing into a cell by liposome or the like have been known, but it has not been possible to put it into practical use because it is difficult to aggregate a target molecule and introduce only a specific molecule into a cell.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIIGATA UNIVERSITY
  • 発明者(英語)
  • CHUMAN Yoshiro
  • KANEKO Atsushi
  • WATARI Miyu
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL ST SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close